Real-world data on two-drug combo for hard-to-treat hodgkin lymphoma
NCT ID NCT07145125
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 222 adults with Hodgkin lymphoma that had returned or not responded to first treatment. Researchers wanted to see how well the combination of brentuximab vedotin and bendamustine worked in everyday medical practice. They measured how long patients stayed free of progression and overall survival, along with side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin and bendamustine
- What this could lead to
- If results are positive, this could confirm a useful treatment option for people whose Hodgkin lymphoma has come back or not responded to initial therapy.
- What could go wrong
- This is a real-world observational study, not a controlled trial, so results may be less reliable. The combination also has known side effects like nerve damage and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH de la Côte Basque, service Hématologie Clinique
Bayonne, France
-
CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire
Bordeaux, France
-
CHU de Caen, service Hématologie Clinique
Caen, France
-
CHU de Toulouse, service Hématologie Clinique
Toulouse, France
-
Institut Paoli Calmettes, service Hématologie Clinique
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.